These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 15653644)

  • 1. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality.
    Elmén J; Thonberg H; Ljungberg K; Frieden M; Westergaard M; Xu Y; Wahren B; Liang Z; Ørum H; Koch T; Wahlestedt C
    Nucleic Acids Res; 2005; 33(1):439-47. PubMed ID: 15653644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LNA incorporated siRNAs exhibit lower off-target effects compared to 2'-OMethoxy in cell phenotypic assays and microarray analysis.
    Puri N; Wang X; Varma R; Burnett C; Beauchamp L; Batten DM; Young M; Sule V; Latham K; Sendera T; Echeverri C; Sachse C; Magdaleno S
    Nucleic Acids Symp Ser (Oxf); 2008; (52):25-6. PubMed ID: 18776235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3.
    Werk D; Wengel J; Wengel SL; Grunert HP; Zeichhardt H; Kurreck J
    FEBS Lett; 2010 Feb; 584(3):591-8. PubMed ID: 20005874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LNA-antisense rivals siRNA for gene silencing.
    Jepsen JS; Wengel J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and sequence motifs of siRNA linked with in vitro down-regulation of morbillivirus gene expression.
    de Almeida RS; Keita D; Libeau G; Albina E
    Antiviral Res; 2008 Jul; 79(1):37-48. PubMed ID: 18394725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications.
    Veedu RN; Wengel J
    Chem Biodivers; 2010 Mar; 7(3):536-42. PubMed ID: 20232325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA.
    Vester B; Wengel J
    Biochemistry; 2004 Oct; 43(42):13233-41. PubMed ID: 15491130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of affinity constants of locked nucleic acid (LNA) and DNA duplex formation using label free sensor technology.
    Möhrle BP; Kumpf M; Gauglitz G
    Analyst; 2005 Dec; 130(12):1634-8. PubMed ID: 16284662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2'-O-Lysylaminohexyl oligonucleotides: modifications for antisense and siRNA.
    Winkler J; Gilbert M; Kocourková A; Stessl M; Noe CR
    ChemMedChem; 2008 Jan; 3(1):102-10. PubMed ID: 17979170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence.
    Fluiter K; Mook OR; Baas F
    Methods Mol Biol; 2009; 487():189-203. PubMed ID: 19301648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent single stranded RNA inhibition.
    Koch T
    Nucleic Acids Symp Ser (Oxf); 2008; (52):45. PubMed ID: 18776245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites.
    Du Q; Thonberg H; Wang J; Wahlestedt C; Liang Z
    Nucleic Acids Res; 2005; 33(5):1671-7. PubMed ID: 15781493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ analysis of single-stranded and duplex siRNA integrity in living cells.
    Raemdonck K; Remaut K; Lucas B; Sanders NN; Demeester J; De Smedt SC
    Biochemistry; 2006 Sep; 45(35):10614-23. PubMed ID: 16939213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.
    Mook OR; Baas F; de Wissel MB; Fluiter K
    Mol Cancer Ther; 2007 Mar; 6(3):833-43. PubMed ID: 17363479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A protocol for designing siRNAs with high functionality and specificity.
    Birmingham A; Anderson E; Sullivan K; Reynolds A; Boese Q; Leake D; Karpilow J; Khvorova A
    Nat Protoc; 2007; 2(9):2068-78. PubMed ID: 17853862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.
    Bartlett DW; Davis ME
    Biotechnol Bioeng; 2007 Jul; 97(4):909-21. PubMed ID: 17154307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional comparison of single- and double-stranded siRNAs in mammalian cells.
    Xu Y; Linde A; Larsson O; Thormeyer D; Elmen J; Wahlestedt C; Liang Z
    Biochem Biophys Res Commun; 2004 Apr; 316(3):680-7. PubMed ID: 15033453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of the adequate detection time for the accurate evaluation of the efficiency of siRNA-induced gene silencing.
    Choi I; Cho BR; Kim D; Miyagawa S; Kubo T; Kim JY; Park CG; Hwang WS; Lee JS; Ahn C
    J Biotechnol; 2005 Nov; 120(3):251-61. PubMed ID: 16095743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. siRNAdb: a database of siRNA sequences.
    Chalk AM; Warfinge RE; Georgii-Hemming P; Sonnhammer EL
    Nucleic Acids Res; 2005 Jan; 33(Database issue):D131-4. PubMed ID: 15608162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The consideration of synthetic short interfering RNA for therapeutic use.
    Li J; Liang Z
    Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):22-9. PubMed ID: 19663819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.